Sign inJoin waitlistJoin the waitlist

Michael Savona

And Professor of Medicine and Cancer Biology · Vanderbilt University Medical Center

Credentials: · · · · ·

History

Vanderbilt University Medical Center
Present
Vanderbilt University Medical Center
Present
Vanderbilt Univ Sch of Med
Present

Hematology and Medical Oncology
University of Michigan
2005–2008
Internal Medicine
University of California Davis Health
2002–2005
Wake Forest Univ Sch of Med
1998–2002

Research

International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
Blood · 2022 · 2,489 citations
Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
NEJM Evidence · 2022 · 764 citations
Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
Nature Medicine · 2020 · 562 citations

RK
Rami Komrokji
45 papers
Mikkael Sekeres
39 papers
Amer Zeidan
36 papers
Guillermo Garcia-Manero
31 papers
Gail Roboz
29 papers
AD
Amy DeZern
26 papers
Alexander Bick
24 papers · 1 as a fellow
DS
David Steensma
22 papers
Elizabeth Griffiths
21 papers
Ashwin Kishtagari
20 papers
Eric Padron
20 papers
Rafael Bejar
20 papers

Grants

F1 Inhibition of OXPHOS to Ameliorate Hyperproliferative Erythropoiesis
National Cancer Institute · R21
Contact PI · $449.5K · Vanderbilt University Medical Center
2026–2028
Single Cell Foundation Model Enabled Drug Discovery for Clonal Hematopoiesis
National Institute on Aging · UG3
PI · $1M · Vanderbilt University Medical Center
2025–2027
Development of a Phenotype-Based Predictive Analytic for Acute Myeloid Leukemia
National Cancer Institute · R01
Contact PI · $3.2M · Vanderbilt University Medical Center
2021–2027
Early Detection of Clonal Hematopoiesis and Leukemia Associated Mutations in Wtc Exposed Firefighters After the 9/11 Attacks
NIOSH · U01
PI · $1.5M · Albert Einstein College of Medicine
2021–2024

Clinical trials

Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients
Principal investigator · Active not recruiting · Phase 1, Phase 2
National Cancer Institute (NCI)
2022–2026
Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia
Principal investigator · Completed · Phase 2
Vanderbilt-Ingram Cancer Center
2016–2024
TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea
Principal investigator · Completed · Phase 1
Vanderbilt-Ingram Cancer Center
2015–2024
Expanded Access Use of INCB052793 to Treat a Single Patient With Myelofibrosis
Principal investigator · No longer available
Incyte Corporation